Nuclear receptor PXR: Discovery of a pharmaceutical anti-target

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Transcriptional induction of the gene encoding cytochrome P450 3A oxygenase (CYP3A) causes a prominent class of dangerous drug-drug interactions wherein one drug accelerates the metabolism of another. In our 1998 JCI paper, we reported the cloning of the human nuclear receptor PXR and demonstrated that it mediates CYP3A induction. We determined that PXR is expressed in liver, acts through a DNA response element located in the CYP3A promoter, and is activated by a structurally diverse collection of drugs that induce CYP3A. Our findings revealed the molecular basis for the CYP3A induction class of drug-drug interactions and provided a highthroughput means for screening out drug candidates with this activity.

Original languageEnglish (US)
Pages (from-to)1388-1389
Number of pages2
JournalJournal of Clinical Investigation
Issue number4
StatePublished - Apr 1 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Nuclear receptor PXR: Discovery of a pharmaceutical anti-target'. Together they form a unique fingerprint.

Cite this